Dynamic changes of serum tumor necrosis factor-α, interleukin-10 in rats with acute liver failure and the hepatoprotective mechanism of tumor necrosis factor-α monoclonal antibody
Yufen Zhang
Abstract
Yufen Zhang
Abstract
Objective To observe the dynamic changes of serum TNF-α, IL-10 of rats with acute liver failure and to explore the hepatoprotective efficacy of anti-tumor necrosis factor alpha monoclonal antibody(anti-TNF-α mAb, Infiximab). Methods Fourteen Wistar rats(7 males and 7 females) were divided into control group(n=7) and treatment group(n=7) randomly. All acute liver failure models of rats was established by hypodermic injection with lipopolysaccharides(10 μg/kg) and intraperitoneal injection with D-Galactosamin(800 mg/kg). Then the rats in the control group were injected with saline hypodermically(1 ml/kg), and the rats in the treatment group were given infiximab injection(5 mg/kg). The levels of serum TNF-α, IL-10 of 2 groups were measured by enzyme-linked immunosorbent assay(ELISA)at the 0, 12, 24, 48 and 72 h and were compared by independent sample t-test between 2 groups. The serum TNF-α, IL-10 levels at different time points in the same group were compared using general linear model-repeated analysis. Results The levels of serum TNF-α reached a peak at 12 h in the control group and gradually decreased at 24, 48 and 72 h. The levels of serum IL-10 rose gradually and significantly at 24 h and peaked at 72 h. The levels of IL-10 and INF-α at 72 h showed significant difference compared with other time points(F =257.31, 227.815, 89.276, 9.984; all in P0.05). The levels of serum TNF-α in the treatment group showed similar changes as the control group, reached a peak at 12 h and gradually decreased at 24, 48 and 72 h. The levels of serum IL-10 increased evidently at 12 and 24 h, but gradually at 48 and 72 h. The levels of IL-10 and TNF-α at 72 h showed significant difference compared with other time point(sF=451.471, 195.105, 26.259, 22.962; all in P0.05). Compared with the control group, the TNF-α levels in the treatment group at 12, 24 and 72 h were significantly lower(t=2.392, 3.393, 2.276; all in P0.05), and the IL-10 levels were higher at 0, 12 and 24 h with significant difference at 12 h(t=-4.556, P=0.002), but lower at 48 and 72 h with significant difference at 72 h(t=7.997, P0.001). Conclusions Serum TNF-α and IL-10 play import roles in the progression of acute liver failure. A large amount of pro-inflammatory cytokines such as TNF-α are induced at the early phase of acute liver failure, and the anti-inflammatory cytokines as IL-10 are induced at the advanced phase. Anti-TNF-α mAb(Infiximab)may probably alleviate liver injury by antagonizing the TNF-α activity and increasing the expression of IL-10 at the early phase.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To observe the dynamic changes of serum TNF-α, IL-10 of rats with acute liver failure and to explore the hepatoprotective efficacy of anti-tumor necrosis factor alpha monoclonal antibody(anti-TNF-α mAb, Infiximab). Methods Fourteen Wistar rats(7 males and 7 females) were divided into control group(n=7) and treatment group(n=7) randomly. All acute liver failure models of rats was established by hypodermic injection with lipopolysaccharides(10 μg/kg) and intraperitoneal injection with D-Galactosamin(800 mg/kg). Then the rats in the control group were injected with saline hypodermically(1 ml/kg), and the rats in the treatment group were given infiximab injection(5 mg/kg). The levels of serum TNF-α, IL-10 of 2 groups were measured by enzyme-linked immunosorbent assay(ELISA)at the 0, 12, 24, 48 and 72 h and were compared by independent sample t-test between 2 groups. The serum TNF-α, IL-10 levels at different time points in the same group were compared using general linear model-repeated analysis. Results The levels of serum TNF-α reached a peak at 12 h in the control group and gradually decreased at 24, 48 and 72 h. The levels of serum IL-10 rose gradually and significantly at 24 h and peaked at 72 h. The levels of IL-10 and INF-α at 72 h showed significant difference compared with other time points(F =257.31, 227.815, 89.276, 9.984; all in P0.05). The levels of serum TNF-α in the treatment group showed similar changes as the control group, reached a peak at 12 h and gradually decreased at 24, 48 and 72 h. The levels of serum IL-10 increased evidently at 12 and 24 h, but gradually at 48 and 72 h. The levels of IL-10 and TNF-α at 72 h showed significant difference compared with other time point(sF=451.471, 195.105, 26.259, 22.962; all in P0.05). Compared with the control group, the TNF-α levels in the treatment group at 12, 24 and 72 h were significantly lower(t=2.392, 3.393, 2.276; all in P0.05), and the IL-10 levels were higher at 0, 12 and 24 h with significant difference at 12 h(t=-4.556, P=0.002), but lower at 48 and 72 h with significant difference at 72 h(t=7.997, P0.001). Conclusions Serum TNF-α and IL-10 play import roles in the progression of acute liver failure. A large amount of pro-inflammatory cytokines such as TNF-α are induced at the early phase of acute liver failure, and the anti-inflammatory cytokines as IL-10 are induced at the advanced phase. Anti-TNF-α mAb(Infiximab)may probably alleviate liver injury by antagonizing the TNF-α activity and increasing the expression of IL-10 at the early phase.
Key concepts: Tumor necrosis factor alpha, Internal medicine, Medicine, Endocrinology, Intraperitoneal injection, Saline, Necrosis, Monoclonal antibody